Connect Biopharma Presents Additional Data from Atopic Dermatitis Trial in China at World Congress of Dermatology
Connect Biopharma Holdings Limited, a global clinical-stage biopharmaceutical company specializing in therapies for chronic inflammatory diseases, unveiled additional findings from its pivotal trial for atopic dermatitis during the 2023 World Congress of Dermatology. The data highlighted the effectiveness and safety of rademikibart (formerly known as CBP-201) in treating moderate-to-severe atopi..